by Eagle Analytical | Jul 15, 2020 | All Posts, COVID-19, FDA
Dexamethasone Sodium Phosphate Added to the List of Drugs for Temporary Compounding The FDA has added Dexamethasone Sodium Phosphate to the list of drugs for temporary compounding by outsourcing facilities and pharmacy compounders during the COVID-19 pandemic. This...
by Eagle Analytical | May 21, 2020 | All Posts, COVID-19, FDA
FDA Updates Guidance On Adverse Reporting During a Pandemic The FDA made an update to their final guidance, “Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic”. The guidance document now includes...
by Eagle Analytical | May 15, 2020 | All Posts, FDA
Updates to FDA’s Purple Book: Database of Licensed Biological Products This week the FDA updated the Purple Book: Database of FDA-Licensed Biological Products. The update is part of a multi-phase enhancement of the database, intended to ultimately improve...
by Eagle Analytical | May 15, 2020 | All Posts, COVID-19, FDA
FDA Announces Update on MOU for Compounding Pharmacies On May 13, a standard memorandum of understanding, also known as a MOU, between the FDA and the states was made available for public viewing as part of the regulatory process. The article states that this marks a...
by Eagle Analytical | May 14, 2020 | All Posts, COVID-19, FDA
FDA Updates Temporary Policy Regarding PPE for Compounders The FDA has issued an update to its Temporary Policy Regarding Non-Standard PPE Practices for Pharmacy Compounders During the COVID-19 Pandemic. In the update, the FDA has clarified that drugs can be...
by Eagle Analytical | May 11, 2020 | All Posts, COVID-19, FDA
Morphine Sulfate & Epinephrine added to COVID-19 Compounding List FDA has updated two guidance documents that describe temporary policies for the compounding of certain human drugs during the COVID-19 public health emergency. The updates add morphine sulfate and...
